Century Therapeutics(IPSC)
Focus: Century Therapeutics is a publicly traded biotechnology company focused on induced pluripotent stem cell (iPSC) therapy platforms for cell-based treatments. The company is early-stage with minimal commercial revenue and a speculative pipeline spanning oncology, autoimmune, and metabolic indications.
Profile data last refreshed 1h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
3-1 this month
Stable — net -1 jobs in 30d
0 added, 1 removed. Backfill posture.
Should You Work at Century Therapeutics?
AI assessmentHigh-risk, early-stage cell therapy play suitable only for scientists seeking bleeding-edge iPSC platform exposure and willing to tolerate existential cash-runway and equity-dilution risk.
Why Work Here
- Public company status with ticker IPSC provides transparency and potential equity upside in a novel iPSC platform space
- High R&D intensity (1628%) signals commitment to platform development with 4 Phase 1 programs and emerging cell therapy pipeline
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$7M
Key Products
Pre-Launch
ANDA pre-launch formulation with no disclosed clinical or commercial data.
Help build intelligence for Century Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.